NCT06305962View on ClinicalTrials.gov

177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 3, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

October 31, 2025

Conditions
PDL1 Gene MutationNon Small Cell Lung CancerSmall Cell Lung Cancer ( SCLC )TNBC, Triple Negative Breast CancerCutaneous MelanomaHNSCCEndometrial Cancer
Interventions
DRUG

177Lu-RAD204

177Lu-RAD204 administered at Imaging (im) and Treatment (tr) doses

Trial Locations (6)

2500

RECRUITING

Wollongong Hospital, Wollongong

2747

RECRUITING

Nepean Hospital, Kingswood

4215

NOT_YET_RECRUITING

Gold Coast University Hospital, Southport

4509

NOT_YET_RECRUITING

Icon Cancer Centre North Lakes, North Lakes

5000

RECRUITING

Cancer Research SA (CRSA), Adelaide

6150

RECRUITING

GenesisCare Murdoch, Murdoch

All Listed Sponsors
lead

Radiopharm Theranostics, Ltd

INDUSTRY